3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Breast
1
Conditions
Head and Neck Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Breast Neoplasms
2
Zollinger-Ellison Syndrome
1
Uterine Cervical Dysplasia
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Obesity
1
Mouth Neoplasms
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Inflammation
1
Gastrinoma
1
Colorectal Neoplasms
1
Chemotherapy Effect
1
Burkitt Lymphoma
1
Interventions
epigallocatechin gallate
2
XENP 1595
2
Etanercept
2
Ascorbic Acid
2
salicylsalicylic acid
1
microcrystalline cellulose
1
ginger extract
1
dapagliflozin
1
cytisine
1
Tablets
1
Sulindac
1
Spirometry
1
Specimen Handling
1
Sodium Salicylate
1
Radiotherapy, Conformal
1
Pregabalin
1
Omeprazole
1
Losartan
1
Ketorolac
1
Interleukin 1 Receptor Antagonist Protein
1
Infliximab
1
Hematologic Tests
1
Diet Therapy
1
Atorvastatin
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Inflammation
×
Omeprazole
×
Clear all
NCT06150898
2025-06-13
KePreSt
Jules Bordet Institute
Phase 2
Recruiting
112 enrolled